Apomorphine is available under the trade name Kynmobi [1].
What is Apomorphine Used For?
Kynmobi is used for the treatment of sudden, OFF episodes in people with Parkinson's disease. OFF episodes are periods when Parkinson's medication is not working well, leading to a return of motor symptoms [1].
How Does Kynmobi Work?
Apomorphine, the active ingredient in Kynmobi, is a dopamine agonist. It works by stimulating dopamine receptors in the brain, which helps to improve motor control in individuals with Parkinson's disease [1].
How is Kynmobi Administered?
Kynmobi is administered as a sublingual film, meaning it dissolves under the tongue [1]. This allows for rapid absorption into the bloodstream [1].
What are the Potential Side Effects of Kynmobi?
Common side effects of Kynmobi include dizziness, drowsiness, nausea, vomiting, diarrhea, headache, and yawning. More serious side effects can include low blood pressure (hypotension), fainting, and central nervous system effects such as hallucinations or psychosis [1].
What Other Forms of Apomorphine Are Available?
Apomorphine has been available in other forms, such as injectable solutions, for many years. These have been used for both acute rescue therapy during OFF episodes and as part of a continuous infusion for more stable symptom management [2].
When Does Kynmobi's Patent Expire?
Information regarding the specific patent expiry dates for Kynmobi is not provided here. However, patent information for pharmaceutical products can be found on resources like DrugPatentWatch.com [3].
Who Manufactures Kynmobi?
Kynmobi is manufactured by Sun Pharmaceutical Industries Ltd. [1].